For the roughly 30,000 Americans living with amyotrophic lateral sclerosis at any given time, the arithmetic of treatment is brutal: most patients survive two to five years from diagnosis, and the small handful of approved therapies extend life by months, not years. Into that gap walks Canurta Therapeutics, a Brampton, Ontario biotech that in February 2025 submitted Pre-IND and Orphan Drug applications to U.S. regulators for CNR-401, a hemp-derived polyphenol candidate it intends to move into ALS trials this year [Canurta, 2026].
The patient population matters here, because ALS is the kind of disease where regulatory pathways genuinely bend. Orphan Drug designation, if granted by the FDA, brings seven years of market exclusivity, tax credits on clinical costs, and waived user fees, all of which can change the economics of a small-molecule program enough to make a venture-backed run at the indication viable. Canurta has not yet disclosed designation status, only that the application was filed.
The standard of care today
For a reader new to ALS, the current standard of care is thin. Riluzole, approved by the FDA in 1995, modestly extends survival. Edaravone, approved in 2017 and now available in oral form, slows functional decline in a subset of patients. Tofersen (Qalsody), approved in 2023, targets the rare SOD1-mutation form of the disease. Beyond these, treatment is supportive: non-invasive ventilation, feeding tubes, physical therapy, multidisciplinary clinics. Most patients combine one or two of the approved drugs with palliative measures and, when eligible, enrollment in clinical trials. Any new mechanism that shows a credible signal in a Phase 1 or Phase 2 readout draws serious attention from the ALS community, which is part of why a preclinical biotech with a novel chemotype can command outsized interest.
The bet
Canurta, founded in 2021 by Akeem Gardner, is built around a class of hemp-derived polyphenols that includes cannflavins A and B, compounds the company says have anti-inflammatory and neuroprotective activity distinct from THC and CBD [Canurta]. Its discovery engine, called PolyKye, uses AI-assisted modeling to identify and rank novel bioactives, with CNR-401 the lead asset moving toward the clinic [Canurta]. The company has secured more than 20 global patents around this chemistry [Newsfile Corp, 2026], which is the kind of IP perimeter investors look for in a botanical drug program where composition-of-matter and method-of-use claims often determine whether a molecule is defensible at all.
The commercial wedge is two-track. The therapeutic pipeline, led by CNR-401 in ALS, is the long-dated, high-value bet. In parallel, the company has described early commercial programs in Brazil and Germany [Canurta, 2026], and operates a cGMP third-party verified, Kosher, and USDA Organic certified facility through Canurta Naturals USA [Canurta Naturals]. In November 2024 the company announced that Canurta Naturals would lead the operational transition at the FSOil facility in Woodburn, Oregon, expanding cGMP botanical extraction capacity in North America [Canurta]. That manufacturing footprint is unusual for a seed-stage biotech and gives Canurta a way to generate revenue and reference-grade material while the drug program advances.
The opportunity
Botanical drugs sit in a regulatory category the FDA formalized in its 2016 Botanical Drug Development guidance, which acknowledges that complex multi-component plant extracts can be approved as drugs without the single-molecule purification path. Very few companies have actually delivered an approval under this framework. If Canurta can move CNR-401 through Phase 1 with a clean safety profile and any hint of biomarker movement, it lands in a category with little competition and a regulatory playbook that increasingly accommodates the science.
Under Gardner's leadership, the company has reported raising over $13 million in funding, including $3.22 million in non-dilutive capital [Newsfile Corp, 2026] [Canurta]. It has been backed by the Accelerator Centre in Waterloo, expanded preclinical work with Washington State University, and gained traction in Canada's C2MP cannabinoid research program [Canurta, 2026]. A separately reported partnership with Applied Pharmaceutical Innovation and Dr. Neal M. Davies at the University of Alberta brings GMP drug-discovery expertise to the hemp polyphenol work [Applied Pharmaceutical Innovation].
Total funding raised | 13.22 | $M
Non-dilutive portion | 3.22 | $M
Reported through 2023 | 5 | $M
The team and traction
Gardner, who studied at the University of Kent [LinkedIn, 2026], previously co-founded Atlas 365, a health and wellness nature products startup [Altitude Accelerator Podcast], and has spent the last several years on the conference circuit explaining the science: presentations at CannMed 2024 in May, the Life Sciences Investor Forum in November 2024 [GlobeNewswire, 2026], and the SUNY Cannabis Conference in January 2025 [Canurta, 2026]. Kelly Boddington and Eric Soubeyrand are listed as mentors and managers at the company [LinkedIn, 2026], adding scientific depth around polyphenol chemistry and plant biology. The company has been preparing for a TSXV listing in 2025 [BioPharmIQ], which would give it public-market access ahead of clinical readouts.
The honest counterfactual
Skeptics will say that botanical drug development has a long history of compelling preclinical data that does not translate. Multi-component extracts are harder to characterize, harder to dose-standardize, and harder to defend in front of an FDA review division than single small molecules, and ALS specifically is a graveyard of programs that looked promising in mouse models. CNR-401 has not yet entered human trials, so all efficacy claims rest on preclinical work. The bull answer is that Canurta has done the unglamorous work that botanical programs usually skip: a patent estate of more than 20 filings [Newsfile Corp, 2026], a cGMP-verified manufacturing base [Canurta Naturals], formal Pre-IND and Orphan Drug submissions [Canurta, 2026], and academic partnerships with API and the University of Alberta that bring pharmacology rigor [Applied Pharmaceutical Innovation]. None of that guarantees a clinical signal, but it removes several of the failure modes that sink earlier botanical efforts before they reach a patient.
What to watch
The next twelve months are concrete. FDA feedback on the Pre-IND package will shape the Phase 1 design and tell investors how the agency views the chemistry-manufacturing-and-controls story for a hemp-derived multi-component drug. A confirmed Orphan Drug designation would be a meaningful tailwind. The TSXV listing, if it materializes, becomes the funding mechanism for actually running the trial. And first-patient-dosed in CNR-401, whenever it occurs, is the moment Canurta stops being a discovery-stage company and becomes a clinical one.
For ALS patients and the families navigating a diagnosis with few good options, none of this changes today's standard of care. But a novel mechanism entering trials is the way the standard of care eventually moves, and Canurta has put itself on the short list of companies worth watching this year.
Pulse Raman covers biotech, digital health, and clinical AI for Startuply.